PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
Executive Summary
Final year of this user fee cycle will include 14% discount, but agency says it is ready for revenue reduction.
You may also be interested in...
Will PDUFA VI Fee Structure Changes Slow Revenue Growth?
User fee revenue expected to break $1bn threshold by FY 2020, but growth looks to be slower than last few years.
Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?
FDA panelists' confusion over biosimilarity and overwhelming approval endorsements following glowing agency reviews suggest the meetings may not be having much impact on FDA deliberations; however, agency sees an opportunity to learn from what its external experts don't understand about biosimilars.
Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed
Industry and FDA are in the process of ratifying the commitment letter for BsUFA II, leaving only the generic drug user fee program still ongoing.